Novo targets blockbuster-heavy 2030 but share slump signals unease
Novo is shaping a future beyond its Wegovy franchise as CEO Maziar Mike Doustdar looks to turn the drugmaker’s fortunes around.
Read the full article on the original site.
Read Full Article